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GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR AND
ITS RECEPTOR CD116 EXPRESSION IN THE SYNOVIUM OF
OSTEOARTHRITIS PATIENTS IS NEGATIVELY CORRELATED WITH PAIN
M.F. Pustjens, S.C. Mastbergen, F.P. Lafeber. Univ. Med. Ctr. Utrecht,
Utrecht, Netherlands
Purpose: Although pain is the most predominant symptom in osteo-
arthritis (OA), the underlying mechanisms are poorly understood. The
synovium is a rich source of many mediators that play a role in OA and
changes in synovitis have been associated with ﬂuctuation of knee pain.
The pro-inﬂammatory cytokine granulatocyte macrophage-colony
stimulating factor (GM-CSF) was recently shown to be correlated with
inﬂammatory synovitis in an animal model of RA, and is implicated to
play a role in pain in OA. The present study evaluates the role of GM-CSF
and its receptor CD116 in the synovium of OA patients in relation to OA
pain.
Methods: Synovial tissue was collected of a cohort of end-stage knee
OA patients (n ¼ 18, mean age 69.5 years, 61% female) selected for total
knee replacement surgery. These patients didn’t use medication in the
year prior to surgery, except for occasionally acetaminophen. Expres-
sion of GM-CSF and CD116 in the synovial sublining and lining or total
was analysed using frozen section immunohistochemistry (IHC-f). To
assess pain levels, the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) questionnaire (100¼ no pain, 0 max-
imum pain) and the Visual Analogue Scale (VAS) were used. Histology
and macroscopy of the synovium were scored using the modiﬁed
Goldenberg and Cohen score and synovial inﬂammation was graded in
three categories: colour, angiogenesis, and ﬁbrillation. Additionally, ex
vivo TNFa, IL-1b, PGE2 and NO levels of the synovial tissue were
measured.
Results: The patients had an average WOMAC score of 55.3 (17.9) and
a VAS score of 30.3mm (20.0). GM-CSF and CD116 were both
expressed in the sublining and lining of the synovial tissue (on average
resp. 424 and 3773 positive cells/mm2 and 948 and 3287 positive cells/
mm2 for GM-CSF and CD116 respectively). A negative correlation was
observed between clinically knee pain (WOMAC) and synovial sublining
(r¼ -0.613, p¼ 0.007), synovial lining (r¼ -0.130, p¼ 0.581) and total (r
¼ -0.520, p ¼ 0.027) GM-CSF expression. Similarly, a negative correla-
tion was found for its receptor CD116 expression versus pain (WOMAC)
in the synovial sublining (r ¼ -0.663, p ¼ 0.003), lining(r ¼ -0.520, p ¼
0.027) and the total score (r ¼ -0.668, p ¼ 0.002). So a high pain level
showed a lower expression of GM-CSF and CD116 in the sublining,
lining or total area of the synovium. Comparable relations were found
when the expression was related to the VAS measurements (GM-CSF
sublining r¼ -0.471 (p¼ 0.048), lining r¼ -0.153, (p¼ 0.545), total score
r ¼ -0.418 (p ¼ 0.085), CD116 sublining r ¼ -0.551 (p ¼ 0.018), lining r ¼
-0.614 (p ¼ 0.007), total score r ¼ 0.612 (p ¼ 0.007)). No correlation was
seen with macroscopic and histologic inﬂammation scores of the
synovium for both GM-CSF and CD116. High levels of GM-CSF expres-
sionwere only correlatedwith low levels of TNFa (r¼ -0.580, p¼ 0.012).
Conclusions: When ex vivo analysed, in human synovial tissue higher
expression of GM-CSF and CD116 correlates with lower levels of the
clinically observed pain in these severe OA patients. This contrasts
earlier OA studies using an animal model. It has been demonstrated that
GM-CSF can have a dual role, exacerbating an inﬂammatory response in
an early phase, and stimulating reparative processes in a later phase,
contributing to healing. Clearly, more research is warranted before
targeting GM-CSF in the synovium is a realistic option to improve pain
in OA.755
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R.E. Miller y, S. Zaki z, S. Ishihara y, P.B. Tran y, C.B. Little z, A-M. Malfait y.
yRush Univ. Med. Ctr., Chicago, IL, USA; zUniv. of Sydney, Sydney, Australia
Purpose: The purpose of this study was to establish a method for
measuring primary knee hyperalgesia using the murine DMMmodel of
experimental osteoarthritis.Methods: DMM or sham surgery was performed in the right knees of
10-week old male C57BL/6 mice (n¼ 5-14/time point). At 0 (pre), 2, 4, 6,
8, or 16 weeks post surgery, knee hyperalgesia was assessed using a
Pressure Application Measurement (PAM) device from Ugo Basile by
two independent blinded users. Mice were restrained by hand and the
PAM device was used to press against either the ipsilateral or con-
tralateral knee. The PAM software guided the user to apply an
increasing amount of force at a constant rate (30 g/s), up to a maximum
of 450 g. If the mouse tried to withdraw its knee, the force at which this
occurred was recorded. If the mouse did not try to withdraw, the
maximum possible force of 450 g was assigned. Two measurements
were taken per knee, one on the medial side, and one on the lateral side,
and the withdrawal force datawere averaged. In addition, the datawere
analyzed in a binary fashion using the chi-square test in which a mouse
was assigned to either withdrawal or no withdrawal categories, based
on whether or not the mouse tried to withdraw its knee on either the
medial or the lateral side.
Results: Prior to DMM surgery, 23% of naïve mice responded to force
applied to the ipsilateral knee, with the meanwithdrawal force of 442 g.
At 2, 4, and 6 weeks post surgery, the majority of both DMM and sham-
operated mice responded to force applied to the operated knees, with
no signiﬁcant difference seen between treatments (Fig 1). By 8 weeks
post surgery, 86% of DMM mice were still withdrawing their ipsilateral
knees, while only 40% of sham mice responded (p ¼ 0.08). Finally, at 16
weeks post surgery, when the DMMmice have moderate to severe joint
damage, 50% of DMMmice responded to force on their ipsilateral knee,
while sham mice had returned to baseline (i.e., 25% responding).
Next, we examined the effect of the treatments on the magnitude of the
withdrawal forces. At 2 and 4 weeks post surgery, both DMM and sham
mice responded to similar forces on their ipsilateral knees (290-336 g),
signiﬁcantly decreased from baseline (p < 0.0001). By 6 weeks post
surgery, the forces at which both sham and DMM mice responded had
signiﬁcantly increased to 402 g and 380 g, respectively, and this
remained the same through 8 weeks post surgery, with no differences
between the two treatments (p < 0.05 vs baseline). At 16 weeks post
surgery, the withdrawal forces had increased for both treatments to 412
g, no longer signiﬁcantly different from baseline.
Interestingly, applying force to the contralateral knee at 2 and 4 weeks
post surgery provoked withdrawal responses in both DMM and sham
mice, in similar numbers of mice and at similar withdrawal forces,
when compared to the ipsilateral responses. At 6-16 weeks post sur-
gery, less than 25% of mice responded to force applied to the con-
tralateral knee, with no differences seen between DMM and shammice.
Conclusions: PAM provides a promising technique to assess primary
knee hyperalgesia associated with OA. From these pilot feasibility
studies, performed by two independent blinded evaluators, the fol-
lowing observations can be made:
Primary knee hyperalgesia peaked during the post-surgical phase (up to
4 weeks post DMM or sham surgery).
By 16 weeks post surgery, 50% of DMM mice continued to withdraw
their knees, while sham mice returned to baseline levels, suggesting
that structural joint damage may play a role in prolonging knee
hyperalgesia.
Finally, bilateral hyperalgesia was detected during the post-surgical
pain period, while the chronic phase of the disease was associated with
hyperalgesia in the ipsilateral knee only.
